Literature DB >> 2167211

Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis.

H Guo1, J H Calkins, M M Sigel, T Lin.   

Abstract

Interstitial tissue of the testis consists of Leydig cells, macrophages, lymphocytes, plasma cells, mast cells and fibroblasts. Previously we have reported that interleukin-1 (IL-1) inhibits Leydig cell androgen production. In the present study, the effect of IL-2 was investigated. Leydig cells (10(5) cells/ml) from adult Sprague-Dawley rats were cultured with or without IL-2 for 24 h. After medium changes, human CG (hCG), 8-bromo-cAMP, or forskolin was added with or without IL-2. Cultures were continued for an additional 24 h, and testosterone and cAMP levels were measured. IL-2 up to 100 U/ml had no effect on basal testosterone production. hCG-stimulated testosterone formation was inhibited in a dose-dependent manner by the addition of IL-2. IL-2 in a concentration of 100 U/ml decreased hCG-induced testosterone formation from 49.6 +/- 3.6 ng/ml (mean +/- SE) to 8.5 +/- 4.2 ng/ml. The hCG dose-response curve was shifted to the right by the addition of IL-2. Maximal testosterone production in response to hCG was reduced 40% in the presence of IL-2 (50 U/ml) without alteration of median effective dose (ED50). IL-2 also inhibited hCG-induced cAMP formation and 8-bromo cAMP- and forskolin-stimulated testosterone production. However, IL-2 did not alter the binding of [125I]hCG to purified Leydig cells. Furthermore, IL-2 significantly inhibited the conversion of 20-OH-cholesterol, 22-OH-cholesterol, pregnenolone, progesterone, 17 alpha-hydroxypregnenolone, and 17 alpha-hydroxyprogesterone to testosterone but did not alter the conversion of dehydroepiandrosterone and androstenedione to testosterone. Our results suggest that a T cell growth factor, IL-2, is a potent inhibitor of steroidogenesis. IL-2 may play a paracrine role in modulating Leydig cell function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167211     DOI: 10.1210/endo-127-3-1234

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

Review 1.  Role of cytokines in testicular function.

Authors:  D B Hales; T Diemer; K H Hales
Journal:  Endocrine       Date:  1999-06       Impact factor: 3.633

Review 2.  Growth factors and testis.

Authors:  G Giordano; P Del Monte; F Minuto
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

3.  Luteinizing hormone pulsatility and computer-assisted analysis of sperm features in patients with Hodgkin's disease.

Authors:  M Magnanti; S Malizia; G Garufi; A Lenzi; A P Anselmo; F Beligotti; A Fabbrini; V Santiemma
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Interleukin-2 affects steroidogenesis and numbers of bovine ovarian granulosa cells but not thecal cellsin vitro.

Authors:  C A Rajagopala Raja; L J Spicer; R E Stewart
Journal:  Endocrine       Date:  1995-12       Impact factor: 3.633

5.  The effects of T cells and their products on in vitro healing of epitenon cell microwounds.

Authors:  B Wòjciak; J F Crossan
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

6.  Modulation of adrenal cell functions by cadmium salts: 2. Sites affected by CdCl2 during unstimulated steroid synthesis.

Authors:  O P Mgbonyebi; C T Smothers; J J Mrotek
Journal:  Cell Biol Toxicol       Date:  1994-02       Impact factor: 6.691

7.  Microarray analysis of androgen-regulated gene expression in testis: the use of the androgen-binding protein (ABP)-transgenic mouse as a model.

Authors:  Peter Petrusz; Durairaj A Jeyaraj; Gail Grossman
Journal:  Reprod Biol Endocrinol       Date:  2005-12-09       Impact factor: 5.211

Review 8.  Insights into the Development of the Adult Leydig Cell Lineage from Stem Leydig Cells.

Authors:  Leping Ye; Xiaoheng Li; Linxi Li; Haolin Chen; Ren-Shan Ge
Journal:  Front Physiol       Date:  2017-06-28       Impact factor: 4.566

9.  Low testosterone predicts hypoxemic respiratory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle.

Authors:  W Vena; A Pizzocaro; G Maida; M Amer; A Voza; A Di Pasquale; F Reggiani; M Ciccarelli; C Fedeli; D Santi; E Lavezzi; A G Lania; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2021-11-18       Impact factor: 5.467

Review 10.  Sepsis as a Pan-Endocrine Illness-Endocrine Disorders in Septic Patients.

Authors:  Weronika Wasyluk; Martyna Wasyluk; Agnieszka Zwolak
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.